Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines

Robert J. Motzer; Eric Jonasch; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B. Bolger; Sam S. Chang; Toni K. Choueiri; Brian A. Costello; Ithaar H. Derweesh; Shilpa Gupta; Steven L. Hancock; Jenny J. Kim; Timothy M. Kuzel; Elaine T. Lam; Clayton Lau; Ellis G. Levine; Daniel W. Lin; M. Dror Michaelson; Thomas Olencki; Roberto Pili; Elizabeth R. Plimack; Edward N. Rampersaud; Bruce G. Redman; Charles J. Ryan; Joel Sheinfeld; Brian Shuch; Kanishka Sircar; Brad Somer; Richard B. Wilder; Mary Dwyer; Rashmi Kumar

doi:10.6004/jnccn.2015.0022

Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas OlenckiRoberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, Rashmi Kumar

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Review article › peer-review

198 Scopus citations

Abstract

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.

Original language	English (US)
Pages (from-to)	151-159
Number of pages	9
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	13
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2015.0022
State	Published - Feb 1 2015

Bibliographical note

Publisher Copyright:
© 2015 by the National Comprehensive Cancer Network. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.6004/jnccn.2015.0022

OpenUrl availability

Full text

Cite this

Motzer, R. J., Jonasch, E., Agarwal, N., Beard, C., Bhayani, S., Bolger, G. B., Chang, S. S., Choueiri, T. K., Costello, B. A., Derweesh, I. H., Gupta, S., Hancock, S. L., Kim, J. J., Kuzel, T. M., Lam, E. T., Lau, C., Levine, E. G., Lin, D. W., Michaelson, M. D., ... Kumar, R. (2015). Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 13(2), 151-159. https://doi.org/10.6004/jnccn.2015.0022

Motzer, RJ, Jonasch, E, Agarwal, N, Beard, C, Bhayani, S, Bolger, GB, Chang, SS, Choueiri, TK, Costello, BA, Derweesh, IH, Gupta, S, Hancock, SL, Kim, JJ, Kuzel, TM, Lam, ET, Lau, C, Levine, EG, Lin, DW, Michaelson, MD, Olencki, T, Pili, R, Plimack, ER, Rampersaud, EN, Redman, BG, Ryan, CJ, Sheinfeld, J, Shuch, B, Sircar, K, Somer, B, Wilder, RB, Dwyer, M & Kumar, R 2015, 'Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 13, no. 2, pp. 151-159. https://doi.org/10.6004/jnccn.2015.0022

@article{8023a60731064161a1937240f427ee93,

title = "Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines",

abstract = "The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.",

author = "Motzer, {Robert J.} and Eric Jonasch and Neeraj Agarwal and Clair Beard and Sam Bhayani and Bolger, {Graeme B.} and Chang, {Sam S.} and Choueiri, {Toni K.} and Costello, {Brian A.} and Derweesh, {Ithaar H.} and Shilpa Gupta and Hancock, {Steven L.} and Kim, {Jenny J.} and Kuzel, {Timothy M.} and Lam, {Elaine T.} and Clayton Lau and Levine, {Ellis G.} and Lin, {Daniel W.} and Michaelson, {M. Dror} and Thomas Olencki and Roberto Pili and Plimack, {Elizabeth R.} and Rampersaud, {Edward N.} and Redman, {Bruce G.} and Ryan, {Charles J.} and Joel Sheinfeld and Brian Shuch and Kanishka Sircar and Brad Somer and Wilder, {Richard B.} and Mary Dwyer and Rashmi Kumar",

year = "2015",

month = feb,

day = "1",

doi = "10.6004/jnccn.2015.0022",

language = "English (US)",

volume = "13",

pages = "151--159",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "2",

}

TY - JOUR

T1 - Kidney cancer, version 3.2015

T2 - Featured updates to the NCCN guidelines

AU - Motzer, Robert J.

AU - Jonasch, Eric

AU - Agarwal, Neeraj

AU - Beard, Clair

AU - Bhayani, Sam

AU - Bolger, Graeme B.

AU - Chang, Sam S.

AU - Choueiri, Toni K.

AU - Costello, Brian A.

AU - Derweesh, Ithaar H.

AU - Gupta, Shilpa

AU - Hancock, Steven L.

AU - Kim, Jenny J.

AU - Kuzel, Timothy M.

AU - Lam, Elaine T.

AU - Lau, Clayton

AU - Levine, Ellis G.

AU - Lin, Daniel W.

AU - Michaelson, M. Dror

AU - Olencki, Thomas

AU - Pili, Roberto

AU - Plimack, Elizabeth R.

AU - Rampersaud, Edward N.

AU - Redman, Bruce G.

AU - Ryan, Charles J.

AU - Sheinfeld, Joel

AU - Shuch, Brian

AU - Sircar, Kanishka

AU - Somer, Brad

AU - Wilder, Richard B.

AU - Dwyer, Mary

AU - Kumar, Rashmi

PY - 2015/2/1

Y1 - 2015/2/1

N2 - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.

AB - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84923445330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923445330&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2015.0022

DO - 10.6004/jnccn.2015.0022

M3 - Review article

C2 - 25691606

AN - SCOPUS:84923445330

SN - 1540-1405

VL - 13

SP - 151

EP - 159

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 2

ER -

Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines

Abstract

Bibliographical note

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this